Sugi Predict

Sugi Predict / Compounds / SCHEMBL71789

SCHEMBL71789

SCHEMBL71789

COC(=O)c1cn(-c2ccccc2)cn1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ MAPT P10636 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ NOTUM Q6P988 1/20 0.46
▸ USP30 Q70CQ3 3/20 0.45
▸ FGFR1 P11362 1/20 0.45
▸ NR4A2 P43354 1/20 0.43
▸ CPB1 P15086 1/20 0.43
▸ CPB2 Q96IY4 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30343253 0.84 CYP2A6 (0.56) MEN1KMT2AKDM4ENOTUMNR4A2
SCHEMBL2229747 0.83 NOTUM (0.66) MEN1KMT2AMAPTNOTUMALDH1A1
SCHEMBL4426800 0.83 MEN1 (0.55) MEN1KMT2AMAPTKDM4ENOTUM
SCHEMBL31434649 0.83 KMT2A (0.55) MEN1KMT2AMAPTNOTUMUSP30
SCHEMBL2653198 0.83 MEN1 (0.55) MEN1KMT2AMAPTNOTUMUSP30
SCHEMBL24812338 0.81 KDM4E (0.45) MEN1KMT2AKDM4ENOTUMUSP30
SCHEMBL69486 0.81 KDM4E (0.55) KDM4EUSP30CPB1CPB2LMNA
SCHEMBL15464718 0.81 MEN1 (0.50) MEN1KMT2AMAPTKDM4ENOTUM
SCHEMBL19017752 0.81 USP30 (0.51) MEN1KMT2AMAPTKDM4EUSP30
SCHEMBL27647990 0.80 MEN1 (0.52) MEN1KMT2AMAPTKDM4EFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540238-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 — — EP disclosed
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-04-10 — — US disclosed
US-11958833-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-04-16 — — US disclosed
WO-2023244818-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
EP-4122929-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2023-01-25 — — EP disclosed
EP-3390391-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2022-09-14 — — EP disclosed
US-20210380562-A1 Novel Compounds MISSION THERAPEUTICS LIMITED (GB) 2021-12-09 — — US disclosed
US-20210380562-A1 Novel Compounds MISSION THERAPEUTICS LIMITED (GB) 2021-12-09 — — US disclosed
US-11130748-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2021-09-28 — — US disclosed
US-11130748-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2021-09-28 — — US disclosed
CN-102036558-A Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors FOREST LAB HOLDINGS LTD 2011-04-27 — — CN disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 — — EP disclosed
WO-2010075356-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-07-01 — — WO disclosed
WO-2010075356-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-07-01 — — WO disclosed
US-20100160323-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-06-24 — — US disclosed
US-20100160323-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-06-24 — — US disclosed
US-20100160323-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-06-24 — — US disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 — — WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 — — US disclosed
EP-1242426-B1 GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS MERCK & CO INC (US) 2007-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160323-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 MEN1 4883/4885KMT2A 1389/4885MAPT 3595/4885
US-20210380562-A1 Novel Compounds USP30, USP20, USP10 MEN1 2541/4885KMT2A 1127/4885MAPT 1554/4885
US-11130748-B2 Compounds USP30, USP20, USP10 MEN1 2529/4885KMT2A 1138/4885MAPT 1744/4885
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 MEN1 4884/4885KMT2A 1352/4885MAPT 3456/4885
US-11958833-B2 Compounds USP30, USP20, USP10 MEN1 2529/4885KMT2A 1138/4885MAPT 1744/4885
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 MEN1 2589/4885KMT2A 366/4885MAPT 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.